Beta Bionics (BBNX) reported a Q4 net loss late Tuesday of $2.72 per diluted share.

The company did not provide a year-ago per-share figure.

Analysts polled by Factset expected a loss of $0.90.

Net sales for the quarter ended Dec. 31 were $20.4 million, up from $8.4 million a year earlier.

Analysts surveyed by Factset expected $20.2 million.

The company set full-year 2025 revenue guidance between $80 million and $85 million.

Analysts polled by Factset expect $85.1 million.

Beta Bionics completed its initial public offering on Jan. 30, listing on the Nasdaq Global Market.